Navigation Links
Noscira Presents Results of Phase IIa Clinical Trial with Nypta(R) (Tideglusib) on Alzheimer's Disease at International Conference on Alzheimer's Disease (ICAD)
Date:7/15/2010

- Treatment with Nypta(R) (Tideglusib) (NP-12) was tolerated and produced positive effects on Alzheimer's patients in four of the five efficacy variables examined in the trial.

- In view of the promising results of this trial, Noscira is preparing the next Phase IIb trial on Alzheimer's patients in order to progress with the clinical development of this novel compound.

MADRID, July 15 /PRNewswire/ -- Noscira, the Grupo Zeltia (ZEL.MC) subsidiary specialized in researching and developing drugs for treating neurodegenerative diseases, presented the results of a Phase IIa clinical trial of Nypta(R) (Tideglusib) on Alzheimer's disease (AD) at the International Conference on Alzheimer's Disease (ICAD), held in Honolulu (Hawaii) from July 10-15, 2010.

Dr. Teodoro del Ser, Director of Clinical Development at Noscira, gave an oral session in the "Therapeutic Strategies" symposium in which he reported that treatment with Nypta(R) (Tideglusib) for 20 weeks was tolerated and had a positive impact on patients' cognitive performance. In order for these results to be statistically significant, they must be confirmed in a Phase IIb trial in which a larger group of patients will be treated for one year.

The Phase IIa trial, which was conducted at three centers in Germany based on advice from experts at the European Medicines Agency (EMA), is the first clinical trial of Nypta(R) (Tideglusib) on a group of Alzheimer's patients. The trial was designed with the primary goal of assessing the safety and tolerability of Nypta(R) (Tideglusib) on these patients.

The
'/>"/>

SOURCE Group Zeltia
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... DUBLIN , June 25, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/8mfjxh/2015_new ) has announced the addition of ... Chemistry and Immunodiagnostics: Global Challenges, Emerging Technologies, ... 2015 New Frontiers in Clinical ... Competitive Landscape is a new seven-country strategic ...
(Date:7/2/2015)... SHENZHEN, China , 2. Juli 2015 /PRNewswire/ ... Hochdurchsatz-Labor für DNA-Screening in Hongkong vom American ... BGI-Einrichtung in Hongkong ist das erste klinische ... ein CAP-Zertifkat erhält und somit ... Ergänzend zu den bestehenden US FDA - ...
(Date:7/2/2015)... July 2, 2015  The Commission for Certification ... ASHP, an organization that represents pharmacists in acute ... of continuing education for recertification of Certified Geriatric ... geriatric programs for this purpose.  ASHP will join ... providers for the CCGP Professional Development Program. ...
Breaking Medicine Technology:New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2BGI erhält Akkreditierung vom College of American Pathologists (CAP) 2Commission for Certification in Geriatric Pharmacy Adds ASHP as Professional Development Program Provider 2
... N.J., Sept. 1, 2011 ConvaTec Inc., a world-leading ... and hospital care today announced that the company has ... that offers a platform of specialized medical devices throughout ... management experience building relationships in key Latin American markets, ...
... Sept. 1, 2011 Kimberly-Clark Health Care (KCHC) ... price increase on synthetic exam gloves due to ... materials, particularly butadiene and acrylonitrile.   ... raw materials along with inflationary pressures have been ...
Cached Medicine Technology:ConvaTec Announces Acquisition of Boston Medical Device 2
(Date:7/3/2015)... ... July 03, 2015 , ... ... speaker lineup for its 2015 Annual Conference , the premiere continuing ... at the Renaissance Orlando at SeaWorld in Orlando, Florida. Speakers include the ...
(Date:7/3/2015)... ... 2015 , ... B. E. Smith, the only full-service leadership ... national chief nursing officer recruitment for Jane Phillips Medical Center in ... B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/3/2015)... ... July 03, 2015 , ... Jennifer Renee Hanes, DO ... Emergency Room , the largest network of independent freestanding emergency rooms in the United ... director of our Sienna Plantation facility,” said Executive Medical Director of First Choice Emergency ...
(Date:7/3/2015)... ... July 03, 2015 , ... Every year, One-to-1 Fitness and the Red ... of the Red Deer community with free fitness training and indoor fitness boot camp ... events and entertainment raised thousands of charity dollars and ended with a $10,000 donation ...
(Date:7/2/2015)... , ... July 02, 2015 , ... sweetFrog Enterprises, LLC. ... opening is now the 19th sweetFrog store located in the Lone Star State. The ... fastest growing companies in 2014. , The store, which opened July 1 at Duke’s ...
Breaking Medicine News(10 mins):Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:sweetFrog Expands Texas Footprint with Location in Canton 2
... Scotia Conservative MP, diagnosed with malignant melanoma is grateful to ... early//. ,The Cadman clinic, instituted in remembrance of ... cancer, was responsible for detecting the presence of the disease ... have an abnormal mole on examination, underwent surgery to have ...
... study conducted by researchers from Cornell University has pointed out ... as a consequence of acid rain// and alteration in the ... fuels and establishment of factories in the U.S. ... in the eastern United States because of its high-priced lumber, ...
... recent study stated that mothers of unimmunised children differ in ... of ways//. ,This is the first large scale study ... approaches are needed to maximise uptake of immunisation in these ... analysed data for 18,488 infants born between September 2000 and ...
... pathways are particularly essential for proper embryo development and ... defects such as cleft palate, spina bifida, reports a ... the University of Colorado, Health Sciences Center, and the ... of the research report, titled ‘p38 and a p38-Interacting ...
... dummy due to different developmental, hygienic or aesthetic reasons. A ... are bad for babies and parents should be in need ... studies conducted over the world since from past decade was ... are prone to reject or breastfeed for a shorter time. ...
... has proved so well in the drug trails, that based ... to patients in the late stages of the disease even ... is speculated that Europe's largest drug maker is all set ... with information and clinical data on Tykerb. They claim that ...
Cached Medicine News:Health News:Growth Of Maple Trees Affected By Acid Rain 2Health News:Growth Of Maple Trees Affected By Acid Rain 3Health News:Mother’s Attitude Towards Immunisation Makes it Inaccessible to Childre 2Health News:GSK’s New Anticancer Drug A Huge Success In Drug trail 2
Anatomic implant shape and easy-to use instrumentation promote implant alignment, stability, and restored joint kinematics....
The NeurOptics Pupillometer is a portable instrument used to measure pupils to screen candidates for refractive procedures and other ophthalmic applications....
... Engineered to closely match the ... Low-profile anatomical design. Titanium construction incorporates ... locking snap-fit screw design prevents screws ... limits the need for X-ray control ...
... 24-Hour Holter, Event, and Pacemaker Monitoring. ... laboratory located in Billerica, MA. The ... to assist physicians in the assessment ... The diagnostic services are offered nationwide ...
Medicine Products: